Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 programMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex ...
Q4 2025 Management View CEO Punit Dhillon outlined recent progress for nimacimab, highlighting the transition from promising early signals to a robust development case. Dhillon stated, "CBeyond ...
Medicus Pharma (NASDAQ:MDCX) said on Monday that new analysis of data from a mid-stage clinical trial of its SkinJect ...
CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...
The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of ...
Allakos Inc. announced that its phase 1 trial of AK006 for chronic spontaneous urticaria (CSU) did not show therapeutic efficacy, leading the company to discontinue its development. While AK006 was ...
AC Development, a Golden-based master and vertical developer, today initiated the first phase of the large-scale mixed-use redevelopment of the CoorsTek manufacturing facility in downtown Golden. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results